HPLC-MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-10 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
=== Relationship Testing === BRT's Relationship Testing division offers services in Paternity Testing and Family reunification Immigration Testing. DNA testing can identify relationships between parent and child, full or half siblings, grandparent and grandchild, uncles or aunts and nieces or nephews, as well as identical and non-identical twins. The Laboratory is accredited by the AABB (formerly, American Association of Blood Banks). Testing can be performed for submission in legal proceedings (court admissible) or for personal knowledge. Application for immigration to the United States and Canada often requires documentation of biological relationship between a petitioner and his or her beneficiary. DNA testing can be used to prove a relationship if documents are absent or challenged. The US Immigration and Naturalization Service (INS) and United States Citizenship and Immigration Services (USCIS) offices accept DNA testing results from AABB accredited laboratories only.
== Secondary structure == Because their backbones are longer than those of normal peptides, β-peptides form disparate secondary structures. The alkyl substituents at both the α and β positions in a β-amino acid favor a gauche conformation about the bond between the α-carbon and β-carbon. This also affects the thermodynamic stability of the structure. Many types of helix structures consisting of β-peptides have been reported. These conformation types are distinguished by the number of atoms in the hydrogen-bonded ring that is formed in solution; 8-helix, 10-helix, 12-helix, 14-helix, and 10/12-helix have been reported. Generally speaking, β-peptides form a more stable helix than α-peptides.
==== Metabolism ==== The metabolism of oxycodone in humans occurs in the liver mainly via the cytochrome P450 system and is extensive (about 95%) and complex, with many minor pathways and resulting metabolites. Around 10% (range 8–14%) of a dose of oxycodone is excreted essentially unchanged (unconjugated or conjugated) in the urine. The major metabolites of oxycodone are noroxycodone (70%), noroxymorphone ("relatively high concentrations"), and oxymorphone (5%). The immediate metabolism of oxycodone in humans is as follows:
Sources: en.wikipedia.org
== Further reading == Brady JE, Humiston GE & Heikkinen H (1980), "Chemistry of the Representative Elements: Part II, The Metalloids and Nonmetals", in General Chemistry: Principles and Structure, 2nd ed., SI version, John Wiley & Sons, New York, pp. 537–91, ISBN 0-471-06315-0 Chedd G (1969), Half-way Elements: The Technology of Metalloids, Doubleday, New York Choppin GR & Johnsen RH (1972), "Group IV and the Metalloids", in Introductory Chemistry, Addison-Wesley, Reading, Massachusetts, pp. 341–57 Dunstan S (1968), "The Metalloids", in Principles of Chemistry, D. Van Nostrand Company, London, pp. 407–39 Goldsmith RH (1982), "Metalloids", Journal of Chemical Education, vol. 59, no. 6, pp. 526527, doi:10.1021/ed059p526 Hawkes SJ (2001), "Semimetallicity", Journal of Chemical Education, vol. 78, no. 12, pp. 1686–87, doi:10.1021/ed078p1686 Metcalfe HC, Williams JE & Castka JF (1974), "Aluminum and the Metalloids", in Modern Chemistry, Holt, Rinehart and Winston, New York, pp. 538–57, ISBN 0-03-089450-6 Miller JS (2019), "Viewpoint: Metalloids – An Electronic Band Structure Perspective", Chemistry – A European Perspective, preprint version, doi:10.1002/chem.201903167 Moeller T, Bailar JC, Kleinberg J, Guss CO, Castellion ME & Metz C (1989), "Carbon and the Semiconducting Elements", in Chemistry, with Inorganic Qualitative Analysis, 3rd ed., Harcourt Brace Jovanovich, San Diego, pp. 742–75, ISBN 0-15-506492-4 Parveen N et al.
==== Early career ==== He was recruited to the AFL by Essendon from the 1990 AFL draft; however, due to a serious hip injury along with other injuries in his junior football career, he was not selected until pick number 79, Essendon's seventh pick and one of the last in the draft. Due to injury, Hird missed out on playing for most of 1991, his first season with the club. At the end of the season, a vote was held on whether to delist him. The majority (4–2) voted in favour of Hird being delisted, but coach Kevin Sheedy, sensing a promising future for the young Hird, voted to keep him. Ultimately, Hird remained with the club. He made his senior debut against St Kilda in 1992 at Waverley Park as a late replacement for former captain Terry Daniher. Hird spent most of the season in the Essendon Reserves, which, under Denis Pagan, won the premiership that season. He achieved regular selection in the Essendon senior team during the 1993 season. In that season, he was a member of what was referred to as the "Baby Bombers", a group of young players (most notably including Hird, Mark Mercuri, Gavin Wanganeen, Dustin Fletcher, Ricky Olarenshaw, David Calthorpe, Paul Hills and Joe Misiti) that played a key role in the side winning the premiership that year. In 1994, Hird won the first of three consecutive best-and-fairest awards, culminating in his 1996 season that earned him a Brownlow Medal. A series of injuries restricted Hird's appearances during the remainder of the 1990s.
=== Benign prostatic hyperplasia === A meta-analysis found that tadalafil is an effective treatment for lower urinary tract symptoms due to benign prostatic hyperplasia and that such treatment had a low rate of adverse effects. Tadalafil is FDA-approved for males as a therapy to treat and prevent symptoms of benign prostatic hyperplasia, such as urinary urgency, hesitancy, weak stream, dribbling, and incontinence. Tadalafil was found to have similar benefits for lower urinary tract symptoms as the usually prescribed tamsulosin.
Sources: en.wikipedia.org
The dissection continues toward the brow and the glabella (the smooth prominence between the eyebrows) until the skin flap is sufficiently mobile to allow its relaxed transposition upon the nose. Under loupe magnification, the distal portion of the forehead flap is de-fatted, down to the subdermal plexus. Yet, the fat-removal should be conservative, especially if the patient is either a tobacco smoker or a diabetic, or both, because such health factors negatively affect blood circulation and tissue perfusion, and thus the timely and correct healing of the surgical scars to the nose. The flap is allowed to perfuse, while the donor site is sutured closed by means of the wide undermining deep to the frontalis muscle. At that time, diluted epinephrine can be injected to the forehead skin, but not to the area(s) near the pedicle of the forehead flap. Moreover, if the distal wound is wider than 25 mm, it usually is not closed by primary intention, with sutures, but is allowed to heal by secondary intention, by re-epithelialisation. The forehead flap is attached to the nasal wound with subcutaneous sutures and skin sutures. If the excess tension of a suture compromises the color of the skin flap, the suture can be loosened, with a skin hook, and observed for 10–15 minutes; if the skin color remains compromised (white), the suture is removed. Upon the complete attachment of the paramedian forehead flap to the nose, the surgical wounds are dressed only with antibiotic ointment. IV.
The enzyme is believed to act on the so-called "quinonoid" form of the starting dihydrobiopterin. This is in contrast to the enzyme dihydrofolate reductase, which normally acts on dihydrofolic acid but can also reduce the isomer, L-erythro-7,8-dihydrobiopterin.
=== Tigrayan Opposition Parties === Opposition groups inside Tigray strongly rebuked the TPLF's actions. On May 11, Salsay Weyane Tigray (Sawet) issued an official statement rejecting the council's return, characterizing the assembly as a "theatrical performance" disconnected from legality and morality. The party accused the TPLF of treating the historical suffering of Tigrayans as a political tool to retain a three-decade monopoly on power. Sawet demanded an immediate halt to the political gamble and called for the creation of an all-inclusive Interim Transitional Government representing alternative civil and political stakeholders.
Indigo dye is an organic compound with a distinctive blue color. Indigo is a natural dye obtained from the leaves of some plants of the Indigofera genus, in particular Indigofera tinctoria. Dye-bearing Indigofera plants were once common throughout the world. Blue colorants are relatively rare. Since indigo is insoluble, it is also referred to as a pigment (C.I. Pigment Blue 66, C.I.). Most indigo dye produced today is synthetic, constituting around 80,000 tonnes each year, as of 2023. It is most commonly associated with the production of denim cloth and blue jeans, where its properties allow for effects such as stone washing and acid washing to be applied quickly.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.